BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2012;32:500-509. [PMID: 22098627 DOI: 10.1111/j.1478-3231.2011.02665.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Özdirik B, Maibier M, Scherf M, Nicklaus JM, Frohme J, Puengel T, Meyer Zum Büschenfelde D, Tacke F, Mueller T, Sigal M. Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis. J Clin Med 2022;11:2479. [PMID: 35566603 DOI: 10.3390/jcm11092479] [Reference Citation Analysis]
2 Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. Front Immunol 2021;12:780641. [PMID: 34925360 DOI: 10.3389/fimmu.2021.780641] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Abuja PM, Zatloukal K, Denk H. Priming, Triggering, Adaptation and Senescence (PTAS): A Hypothesis for a Common Damage Mechanism of Steatohepatitis. Int J Mol Sci 2021;22:12545. [PMID: 34830427 DOI: 10.3390/ijms222212545] [Reference Citation Analysis]
4 Braun F, Homeyer I, Alachkar N, Huber TB. Immune-mediated entities of (primary) focal segmental glomerulosclerosis. Cell Tissue Res 2021. [PMID: 33907872 DOI: 10.1007/s00441-021-03454-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kozakiewicz M, Wlazeł RN. Does Soluble Urokinase-Type Plasminogen Activator Receptor Level Predicts the Occurrence of Inflammatory Complications in Maxillofacial Surgery? Applied Sciences 2021;11:2192. [DOI: 10.3390/app11052192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Butt S, Jeppesen JL, Iversen LV, Fenger M, Eugen-Olsen J, Andersson C, Jacobsen S. Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis. PLoS One 2021;16:e0247256. [PMID: 33617568 DOI: 10.1371/journal.pone.0247256] [Reference Citation Analysis]
7 Petersen JEV, Kallemose T, Barton KD, Caspi A, Rasmussen LJH. Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis. BMJ Open 2020;10:e036125. [PMID: 32690515 DOI: 10.1136/bmjopen-2019-036125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Chen SH, Wan QS, Wang T, Zhang KH. Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis. Biomed Res Int 2020;2020:7170457. [PMID: 32280697 DOI: 10.1155/2020/7170457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li G, Lin J, Peng Y, Qin K, Wen L, Zhao T, Feng Q. Curcumol may reverse early and advanced liver fibrogenesis through downregulating the uPA/uPAR pathway. Phytother Res 2020;34:1421-35. [PMID: 31989700 DOI: 10.1002/ptr.6616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt KD, Lee SS; Cirrhotic Cardiomyopathy Consortium. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology 2020;71:334-45. [PMID: 31342529 DOI: 10.1002/hep.30875] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 44.0] [Reference Citation Analysis]
11 Kumar P, Kakar A, Gogia A, Waziri N. Evaluation of soluble urokinase-type plasminogen activator receptor (suPAR) quick test for triage in the emergency department. J Family Med Prim Care 2019;8:3871-5. [PMID: 31879628 DOI: 10.4103/jfmpc.jfmpc_116_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wei C, Zhu K, Reiser J. Soluble Urokinase Receptor and Liver Disease. Clin Liver Dis (Hoboken) 2019;14:163-6. [PMID: 31879556 DOI: 10.1002/cld.850] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Long D, Wang Y, Wang H, Wu X, Yu L. Correlation of Serum and Ascitic Fluid Soluble Form Urokinase Plasminogen Activator Receptor Levels With Patient Complications, Disease Severity, Inflammatory Markers, and Prognosis in Patients With Severe Acute Pancreatitis. Pancreas 2019;48:335-42. [PMID: 30768571 DOI: 10.1097/MPA.0000000000001247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Garnæs E, Mortensen C, Hobolth L, Andersen O, Nehlin J, Møller S. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis. PLoS One 2019;14:e0220697. [PMID: 31465463 DOI: 10.1371/journal.pone.0220697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Huang Z, Wang N, Huang S, Chen Y, Yang S, Gan Q, Ye H, Liu B, Pan C. Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure. Gastroenterol Res Pract 2019;2019:3467690. [PMID: 31191644 DOI: 10.1155/2019/3467690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Haupt TH, Rasmussen LJH, Kallemose T, Ladelund S, Andersen O, Pisinger C, Eugen-Olsen J. Healthy lifestyles reduce suPAR and mortality in a Danish general population study. Immun Ageing 2019;16:1. [PMID: 30679937 DOI: 10.1186/s12979-018-0141-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
17 Kolber W, Kuśnierz-Cabala B, Dumnicka P, Maraj M, Mazur-Laskowska M, Pędziwiatr M, Ceranowicz P. Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis. J Clin Med 2018;7:E305. [PMID: 30262764 DOI: 10.3390/jcm7100305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
18 Saraiva GN, do Rosário NF, Medeiros T, Leite PEC, Lacerda GS, de Andrade TG, de Azeredo EL, Ancuta P, Almeida JR, Xavier AR, Silva AA. Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C. Mediators Inflamm 2018;2018:8578051. [PMID: 29977152 DOI: 10.1155/2018/8578051] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
19 Hodges GW, Bang CN, Eugen-Olsen J, Olsen MH, Boman K, Ray S, Kesäniemi AY, Jeppesen JL, Wachtell K. SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis. Open Heart 2018;5:e000743. [PMID: 29387432 DOI: 10.1136/openhrt-2017-000743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Kiiski H, Jalkanen V, Ala-Peijari M, Hämäläinen M, Moilanen E, Peltola J, Tenhunen J. Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage. Front Neurol 2017;8:144. [PMID: 28458650 DOI: 10.3389/fneur.2017.00144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Udomsinprasert W, Honsawek S, Jirathanathornnukul N, Chongsrisawat V, Poovorawan Y. Elevation of serum urokinase plasminogen activator receptor and liver stiffness in postoperative biliary atresia. World J Hepatol 2016; 8(33): 1471-1477 [PMID: 27957246 DOI: 10.4254/wjh.v8.i33.1471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Rasmussen LJ, Ladelund S, Haupt TH, Ellekilde G, Poulsen JH, Iversen K, Eugen-Olsen J, Andersen O. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J 2016;33:769-75. [PMID: 27590986 DOI: 10.1136/emermed-2015-205444] [Cited by in Crossref: 49] [Cited by in F6Publishing: 62] [Article Influence: 8.2] [Reference Citation Analysis]
23 Sandø A, Schultz M, Eugen-Olsen J, Rasmussen LS, Køber L, Kjøller E, Jensen BN, Ravn L, Lange T, Iversen K. Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial. Scand J Trauma Resusc Emerg Med 2016;24:100. [PMID: 27491822 DOI: 10.1186/s13049-016-0290-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
24 Sevgi DY, Bayraktar B, Gündüz A, Özgüven BY, Togay A, Bulut E, Uzun N, Dökmetaş İ. Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien Klin Wochenschr 2016;128:28-33. [PMID: 26546355 DOI: 10.1007/s00508-015-0886-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
25 Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, D'Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D, Mikulak J. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Sci Rep 2015;5:13647. [PMID: 26380915 DOI: 10.1038/srep13647] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
26 Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion. J Biol Chem 2015;290:14798-809. [PMID: 25837250 DOI: 10.1074/jbc.M115.637488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
27 Riehle KJ, Johnson MM, Johansson F, Bauer RL, Hayes BJ, Gilbertson DG, Haran AC, Fausto N, Campbell JS. Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation. Biochim Biophys Acta 2014;1842:318-25. [PMID: 24269585 DOI: 10.1016/j.bbadis.2013.11.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
28 Lerschmacher O, Koch A, Streetz K, Trautwein C, Tacke F. [Management of decompensated liver cirrhosis in the intensive care unit]. Med Klin Intensivmed Notfmed. 2013;108:646-656. [PMID: 24030843 DOI: 10.1007/s00063-013-0259-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
29 Maas RJ, Deegens JK, Wetzels JF. Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol. 2013;28:1041-1048. [PMID: 23515666 DOI: 10.1007/s00467-013-2452-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
30 Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, Aaby P, Laursen AL, Wejse C, Eugen-Olsen J; Bissau HIV cohort study group. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open 2012;2:e001587. [PMID: 23151393 DOI: 10.1136/bmjopen-2012-001587] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
31 Wang L, Ly CM, Ko CY, Meyers EE, Lawrence DA, Bernstein AM. uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin. Invest Ophthalmol Vis Sci 2012;53:4765-75. [PMID: 22700714 DOI: 10.1167/iovs.12-10042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
32 Seidler S, Zimmermann HW, Weiskirchen R, Trautwein C, Tacke F. Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes. BMC Gastroenterol. 2012;12:38. [PMID: 22530792 DOI: 10.1186/1471-230x-12-38] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
33 Koch A, Zimmermann HW, Baeck C, Schneider C, Yagmur E, Trautwein C, Tacke F. Serum NT-proCNP concentrations are elevated in patients with chronic liver diseases and associated with complications and unfavorable prognosis of cirrhosis. Clin Biochem 2012;45:429-35. [PMID: 22285383 DOI: 10.1016/j.clinbiochem.2012.01.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
34 Koch A, Tacke F. Why high suPAR is not super--diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU. Crit Care 2011;15:1020. [PMID: 22182777 DOI: 10.1186/cc10577] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]